UK markets close in 2 hours 38 minutes

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5055+0.1493 (+41.91%)
At close: 04:00PM EDT
0.5638 +0.06 (+11.53%)
Pre-market: 08:52AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3562
Bid0.5043 x 1400
Ask0.5105 x 1400
Day's range0.4300 - 0.6190
52-week range0.3500 - 2.2100
Avg. volume7,441,445
Market cap244.115M
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings date26 May 2024 - 30 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.23
  • Bloomberg

    23andMe Jumps as CEO Floats Taking DNA Tester Private

    (Bloomberg) -- DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.Most Read from BloombergDubai Grinds to Standstill as Flooding Hits CityElon Wants His Money BackSingapore Loses ‘World’s Best Airport’ Crown to QatarRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingRed Lobster Considers Bankruptcy to Deal With Leases and La

  • GlobeNewswire

    23andMe announces CEO’s intention to pursue a potential take-private

    SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E

  • Reuters

    23andMe CEO Wojcicki considering taking firm private, filing shows

    Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.